Participants who receive daily activity message for Pulmonary Embolism

N/A
Recruiting
Led By Daniel Lachant, DO
Research Sponsored by University of Rochester
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up12 weeks
Awards & highlights

Study Summary

This trial will help improve understanding of how to better manage acute pulmonary embolism.

Eligible Conditions
  • Pulmonary Embolism

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
mean change in mean amplitude deviation as measured by actigraphy
Actigraphy
Secondary outcome measures
mean change in 6 minute walking distance
mean change in activity as measured by Actigraph
mean change in carbon dioxide production during a 6 minute walk
+8 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Participants who receive daily activity messageExperimental Treatment1 Intervention
The intervention group will receive instructions for a daily activity sent through SMS text message or email.
Group II: Participants who receive control messagePlacebo Group1 Intervention
The control group will receive daily messages to help with blinding sent through text message or email. The messages will not include activity tasks and will include phrases such as "I hope you have a good day".

Find a site

Who is running the clinical trial?

University of RochesterLead Sponsor
819 Previous Clinical Trials
515,414 Total Patients Enrolled
1 Trials studying Pulmonary Embolism
218 Patients Enrolled for Pulmonary Embolism
American College of Chest PhysiciansOTHER
5 Previous Clinical Trials
1,935 Total Patients Enrolled
1 Trials studying Pulmonary Embolism
746 Patients Enrolled for Pulmonary Embolism
Daniel Lachant, DOPrincipal Investigator
University of Rochester

Media Library

Daily Activity Text Clinical Trial Eligibility Overview. Trial Name: NCT05571189 — N/A
Pulmonary Embolism Research Study Groups: Participants who receive daily activity message, Participants who receive control message
Pulmonary Embolism Clinical Trial 2023: Daily Activity Text Highlights & Side Effects. Trial Name: NCT05571189 — N/A
Daily Activity Text 2023 Treatment Timeline for Medical Study. Trial Name: NCT05571189 — N/A
Pulmonary Embolism Patient Testimony for trial: Trial Name: NCT05571189 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any open positions available to participate in this experiment?

"Per the information available on clinicaltrials.gov, this experiment is open for recruitment. It was originally announced on November 7th 2022 and has had its details updated recently, as of November 8th 2022."

Answered by AI

How many participants are enrolled in this clinical trial?

"Affirmative, the information hosted on clinicaltrials.gov states that this medical investigation is presently seeking participants. Initially posted on November 7th 2022 and recently updated on November 8th 2022, it requires 80 individuals from 1 centre to take part in the study."

Answered by AI

Who else is applying?

What state do they live in?
Kentucky
What site did they apply to?
University of Rochester Medical Center
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
3+

Why did patients apply to this trial?

Just to learn more about my condition and to learn to live with it everyday.
Patient
~49 spots leftby Mar 2025